|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/30/2013 7:21:44 AM
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics, announced the pricing of initial public offering of 3.318 million common shares at $10.00 per share, the low end of the estimated range. The offering is expected to close on January 31, 2013. In an amended regulatory filing with the U.S. Securities and Exchange Commission on January 8, the company had expected to price the initial public offering of 2.275 million common shares between $10 and $12 per share. The New York-based company expects gross proceeds from the initial public offering to be $33.18 million, before expenses. Stemline has granted the representative of the underwriters a 45-day option to purchase up to 497,647 additional shares of common stock to cover over-allotments, if any. The company said that the shares are expected to begin trading on the NASDAQ Capital Market under the symbol "STML" on January 29, 2013.
|
|
|
|
|
|
|
|
|
|
|